Natalizumab Elan Pharma
Land: Den Europæiske Union
Sprog: engelsk
Kilde: EMA (European Medicines Agency)
Offentlige vurderingsrapport
(PAR)
25-01-2008
Nogle dokumenter til dette produkt er ikke tilgængelige i øjeblikket, du kan sende en anmodning til vores kundeservice, og vi vil underrette dig, så snart vi er i stand til at få dem.
Send anmodning.
Send anmodning.
Aktiv bestanddel:
natalizumab
Tilgængelig fra:
Elan Pharma International Ltd.
ATC-kode:
L03AD
INN (International Name):
natalizumab
Terapeutisk gruppe:
Immunostimulants,
Terapeutisk område:
Crohn Disease
Terapeutiske indikationer:
Treatment of moderately to severely active Crohn's disease for the reduction of signs and symptoms, and the induction and maintenance of sustained response and remission, in patients who have not responded despite a full and adequate course of therapy with a corticosteroid and an immunosuppressant; or are intolerant to or have medical contraindications to such therapies.
Autorisation status:
Refused
